In summary, combining IFIT3-targeted therapies with existing immunotherapies (e.g., immune checkpoint inhibitors or radiotherapy in combination with immunotherapy) may provide a synergistic approach to overcoming tumor immune resistance. Here, IFIT3 is linked to neoplasm.